Abstract
Biotechnology Law ReportVol. 26, No. 1 Regulatory Affairs—PharmaceuticalSenate Finally Approves Von Eschenbach as FDA Commissioner; FDA Proposes New Rules for Access to Experimental Drugs; Submitting Genomics Data to FDA; GAO Looks at Drug Development; Too Much Epo?Published Online:21 Mar 2007https://doi.org/10.1089/blr.2006.9991AboutSectionsPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail FiguresReferencesRelatedDetails Volume 26Issue 1Feb 2007 InformationMary Ann Liebert, Inc.To cite this article:Senate Finally Approves Von Eschenbach as FDA Commissioner; FDA Proposes New Rules for Access to Experimental Drugs; Submitting Genomics Data to FDA; GAO Looks at Drug Development; Too Much Epo?.Biotechnology Law Report.Feb 2007.16-18.http://doi.org/10.1089/blr.2006.9991Published in Volume: 26 Issue 1: March 21, 2007PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
